Immune checkpoint inhibitors (ICIs) represent one of the main steps forward for the treatment of advanced or metastatic non-small-cell lung cancer (NSCLC), without oncogenic driver alterations. Despite this recent progress, only a minority of patients achieve a broad and durable benefit and another proportion report poor survival and sometimes fast disease progression, confirming the need to optimise the patient's selection. To date, several issues are unsolved about how to personalise the immunotherapy treatment for individual patients. In this review, analysing data from pivotal randomised clinical trials (RCTs), we discuss patient baseline clinical and demographic features, including sex, age, ECOG performance status, smoking habit and specific site of metastases (liver, bone and brain) that may influence the efficacy outcomes in patients treated with ICIs. The high performance of the ICIs blurred the vision on different efficacy-limiting factors, which require extensive evaluation to improve the understanding of the tumour-specific immune response, in which clinical drivers could be useful for better patient stratification.
Clinical features affecting survival in metastatic NSCLC treated with immunotherapy : A critical review of published data / A. Passaro, I. Attili, S. Morganti, E. Del Signore, L. Gianoncelli, G. Spitaleri, V. Stati, C. Catania, G. Curigliano, F. de Marinis. - In: CANCER TREATMENT REVIEWS. - ISSN 0305-7372. - 89:(2020 Sep), pp. 102085.1-102085.10. [10.1016/j.ctrv.2020.102085]
Clinical features affecting survival in metastatic NSCLC treated with immunotherapy : A critical review of published data
S. Morganti;L. Gianoncelli;G. CuriglianoConceptualization
;
2020
Abstract
Immune checkpoint inhibitors (ICIs) represent one of the main steps forward for the treatment of advanced or metastatic non-small-cell lung cancer (NSCLC), without oncogenic driver alterations. Despite this recent progress, only a minority of patients achieve a broad and durable benefit and another proportion report poor survival and sometimes fast disease progression, confirming the need to optimise the patient's selection. To date, several issues are unsolved about how to personalise the immunotherapy treatment for individual patients. In this review, analysing data from pivotal randomised clinical trials (RCTs), we discuss patient baseline clinical and demographic features, including sex, age, ECOG performance status, smoking habit and specific site of metastases (liver, bone and brain) that may influence the efficacy outcomes in patients treated with ICIs. The high performance of the ICIs blurred the vision on different efficacy-limiting factors, which require extensive evaluation to improve the understanding of the tumour-specific immune response, in which clinical drivers could be useful for better patient stratification.File | Dimensione | Formato | |
---|---|---|---|
Passaro and Curigliano CTR 2020.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
590.13 kB
Formato
Adobe PDF
|
590.13 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.